Mammary Cell News Volume 11.17 | May 9 2019

TOP STORY

SREBP1 Drives Keratin-80-Dependent Cytoskeletal Changes and Invasive Behavior in Endocrine-Resistant ERα Breast Cancer

Scientists demonstrated that the type II keratin topological associating domain underwent epigenetic reprogramming in aromatase inhibitor-resistant cells, leading to keratin-80 (KRT80) upregulation. KRT80 expression was driven by de novo enhancer activation by sterol regulatory element-binding protein 1. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

The Transcription Factor CBFB Suppresses Breast Cancer through Orchestrating Translation and Transcription

Researchers report a noncanonical role of CBFB in translation regulation. RNA immunoprecipitation followed by deep sequencing revealed that cytoplasmic CBFB bound to hundreds of transcripts and regulated their translation. [Nat Commun] Full Article

Metabolically Activated Adipose Tissue Macrophages Link Obesity to Triple-Negative Breast Cancer

Metabolically activated phenotype macrophages released IL-6 in an NADPH oxidase 2-dependent manner, which signaled through glycoprotein 130 on triple-negative breast cancer cells to promote stem-like properties including tumor formation. [J Exp Med] Abstract | Press Release | Graphical Abstract

KLF5 Regulated lncRNA RP1 Promotes the Growth and Metastasis of Breast Cancer via Repressing p27kip1 Translation

Investigators characterized a novel long noncoding RNA (lncRNA), RP1-5O6.5 (termed as RP1). Gain-of-function and loss-of-function assays showed that RP1 promoted the proliferation and metastasis of breast cancer cells in vitro and in vivo. [Cell Death Dis] Full Article

Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets

The authors applied a machine-learning-based approach (idTRAX) to triple-negative breast cancer cell lines and efficiently identified cancer-selective targets. They found that inhibiting AKT selectively killed MFM-223 and CAL148 cells, while inhibiting FGFR2 only killed MFM-223. [Cell Chem Biol] Abstract | Graphical Abstract

High-Resolution Imaging and Single-Cell Analysis via Laser Ablation-Inductively Coupled Plasma-Mass Spectrometry for the Determination of Membranous Receptor Expression Levels in Breast Cancer Cell Lines Using Receptor-Specific Hybrid Tracers

Researchers assessed the suitability of laser ablation-inductively coupled plasma-mass spectrometry as a micro-analytical technique for the localization and quantification of membranous receptors in heterogeneous cell samples that expressed both the membrane-bound receptors C-X-C chemokine receptor type 4 and epidermal growth factor receptor. [Anal Chim Acta] Abstract | Graphical Abstract

Dual Inhibition of Glutaminase and Carnitine Palmitoyltransferase Decreases Growth and Migration of Glutaminase Inhibition-Resistant Triple-Negative Breast Cancer Cells

The authors classified cell lines as CB-839 sensitive or resistant according to their growth responses to CB-839. Compared with sensitive cells, resistant cells were less glutaminolytic and, upon CB-839 treatment, exhibited a smaller decrease in ATP content and less mitochondrial fragmentation, an indicator of poor mitochondrial health. [J Biol Chem] Abstract | Full Article

Exploring Cellular Uptake, Accumulation and Mechanism of Action of a Cationic Ru-Based Nanosystem in Human Preclinical Models of Breast Cancer

Scientists demonstrated that autophagy involvement behind the antiproliferative action of a ruthenium(III)-complex incorporated into a cationic nanosystem proved to be hitherto one of the most effective within the suite of nucleolipidic formulations they developed for the in vivo transport of anticancer ruthenium(III)-based drugs. [Sci Rep] Full Article

VANGL2 Regulates Luminal Epithelial Organization and Cell Turnover in the Mammary Gland

Investigators utilized a panel of Vang1 and Vangl2 mouse alleles to examine the requirement of VANGL family members in the murine mammary gland. They showed that Vang1CKO^Δ/Δ glands displayed normal branching while Vangl2^flox/flox and Vangl2^Lp/Lp tissue exhibited several phenotypes. [Sci Rep] Full Article

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Mechanisms of Genomic Instability in Breast Cancer

The authors comprehensively discuss the recent advances on the mechanisms of genomic instability (GI) in breast cancer, highlighting DNA repair defects and chromosome segregation errors during mitosis. They further review the clinical implications and therapeutic potential of targeting GI in the era of precision medicine. [Trends Mol Med] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER⁺ Metastatic Breast Cancer’

Sermonix Pharmaceuticals LLC announced that it will present a poster on the performance of its lead investigational drug, lasofoxifene. [Press release from Sermonix Pharmaceuticals LLC discussing research to be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo Company, Limited and AstraZeneca announced positive topline results for the pivotal Phase II DESTINY-Breast01 trial of [fam-] trastuzumab deruxtecan. The HER2 targeting antibody drug conjugate was evaluated in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine. [Daiichi Sankyo Company, Ltd] Press Release

Cotinga Pharmaceuticals Releases Early Interim Data of Phase Ib/IIa Combination Trial of COTI-2 in Solid Tumors

Cotinga Pharmaceuticals Inc. announced that the company has released early interim data of its ongoing Phase Ib/IIa clinical trial of COTI-2 plus cisplatin in solid tumors. [Cotinga Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Press Release

Onxeo Announces Treatment of First Patient in DRIIV-Ib, a Phase Ib Clinical Trial of AsiDNA™ in Combination with Chemotherapy

Onxeo S.A. announces a new milestone in the clinical development of AsiDNA™ with the treatment of the first patient in DRIIV-Ib, a phase Ib clinical study of AsiDNA™, a first-in-class tumor DNA repair inhibitor, in combination with carboplatin and with carboplatin plus paclitaxel, in patients with solid tumors eligible to such treatments. [Onxeo S.A.] Press Release

CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals

CytoDyn Inc. announced that in a murine xenograft human breast cancer metastatic model, after nine weeks, compared with untreated mice at eight weeks, the leronlimab treated mice continued to have a >98% reduction in metastatic burden. [CytoDyn, Inc.] Press Release

FDA Approves Genentech’s Kadcyla for Adjuvant Treatment of People with HER2-Positive Early Breast Cancer with Residual Invasive Disease after Neoadjuvant Treatment

Genentech announced that the FDA has approved Kadcyla^® for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin^®-based treatment. [Genentech, Inc.] Press Release

FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in Metastatic Triple-Negative Breast Cancer

CytoDyn Inc. announced that the FDA has granted Fast Track Designation to leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. [CytoDyn, Inc.] Press Release

White House to Convene Committee to Address Research Obstacles

The leaders of the White House Office of Science and Technology, National Institutes of Health, National Science Foundation, National Institute of Standards and Technology, and the Department of Energy’s science division have formed a committee “to address issues facing the US research community,” President Donald Trump’s administration announced. [The Scientist] Editorial

Black Academics Publish One-Fifth of South Africa’s Research

The proportion of scientific articles published by academics in South Africa who are black, colored or of Indian origin has risen almost tenfold since the end of apartheid, to about one-third, finds a report on scholarly publishing in the country. [Nature News] Editorial

NEW European Society for Medical Oncology (ESMO) 2019 Congress
September 27-October 1, 2019
Barcelona, Spain

Visit our events page to see a complete list of events in the community.

NEW Research Assistant – Anti-Breast Cancer Drugs (United Arab Emirates University)

Postdoctoral Fellowship – Redox Biology of Breast and Lung Cancer (Washington University School of Medicine)

Postdoctoral Fellowship – PcG-Mediated Mechanisms in Breast Cancer (University of Miami)

Postdoctoral Research Position – Molecular Biology & Cancer Research (Augusta University)

Postdoctoral Fellowship – Tumor Suppressor CSMD1 (Lund University)

Postdoctoral Position – Breast Cancer Research (Massachusetts General/Harvard Medical School)

Faculty Position – Breast and Ovarian Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Research (Washington University School of Medicine)

Professor – Breast Cancer (University Hospitals Cleveland Medical Center)

Postdoctoral Associate – Cancer Immunology (The Jackson Laboratory)

Postdoctoral Fellow – Cancer Bioinformatics (BC Cancer Research Center, PHSA)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.